Kymera Therapeutics KYMR
NASDAQ KYMR
$117.42 +0.14 (+0.12%)
As of: Sep 4, 2026 · 3:55 PM EDT

Kymera Therapeutics (KYMR) Non Operating Interest Expenses (2019 - 2026)

Analysis

Kymera Therapeutics (KYMR) Non Operating Interest Expenses (2019 - 2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non Operating Interest Expenses (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn 11.00 Mn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn -1.00 Mn
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn -
5 Revolution Medicines 44.33 Bn 44.33 Bn - 23.78 Mn
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn 39.74 Mn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn 82.05 Mn
8 Royalty Pharma 28.45 Bn 27.61 Bn - 93.62 Mn
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn 20.27 Mn
10 Kymera Therapeutics 11.52 Bn 10.83 Bn - 81,000.00
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 81,000.00
Mar 31, 2026 61,000.00
Dec 31, 2025 90,000.00
Sep 30, 2025 98,000.00
Jun 30, 2025 108,000.00
Mar 31, 2025 72,000.00
Dec 31, 2024 59,000.00
Sep 30, 2024 60,000.00
Jun 30, 2024 61,000.00
Mar 31, 2024 69,000.00
Dec 31, 2023 52,000.00
Sep 30, 2023 41,000.00
Jun 30, 2023 48,000.00
Mar 31, 2023 55,000.00
Dec 31, 2022 59,000.00
Sep 30, 2022 36,000.00
Jun 30, 2022 41,000.00
Mar 31, 2022 41,000.00
Dec 31, 2021 51,000.00
Sep 30, 2021 70,000.00